Browsing by Author Pedersen, Terje R

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2006Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) TrialsBarter, Philip; Cater, Nilo B; Demicco, David A; Gaffney, Michael; Holme, Ingar; Kastelein, John J.P.; LaRosa, John C.; Olsson, Anders G; Pedersen, Terje R; Szarek, M; Central Clinical School: Heart Research InstituteAbstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials, Circulation (Baltimore), vol.114, N/A,pp II_713-II_714
2017Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialKeech, Anthony (Tony); Ceska, Richard; De Ferrari, Gaetano M; et al, Various; Gaciong, Zbigniew A; Giugliano, Robert P; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Park, Jeong-Gun; Pedersen, Terje R; Toth, Kalman; NH&MRC Clinical Trials CentreClinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, The Lancet, vol.390, 10106, 2017,pp 1962-1971
2017Cognitive function in a randomized trial of evolocumabKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Im, Kyungah; Kanevsky, Estella; Kurtz, C; Mach, Francois; Ott, Brian R.; Pedersen, Terje R; Robinson, Jennifer; Sabatine, Marc S.; Schneider, J; Sever, Peter; Wang, Huei; Wasserman, Scott M; Zavitz, Kenton H.; NH&MRC Clinical Trials CentreCognitive function in a randomized trial of evolocumab, New England Journal of Medicine, vol.377, 7, 2017,pp 633-643
2017Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular diseaseKeech, Anthony (Tony); Fonarow, Gregg; Giugliano, Robert P; Lindgren, Peter; Pedersen, Terje R; Qian, Yi; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; van Hout, Ben; Villa, Guillermo; NH&MRC Clinical Trials CentreCost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, JAMA Cardiology, vol.2, 10, 2017,pp 1069-1078
2013Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-AnalysisKirby, Adrienne; Sullivan, David; Amarenco, Pierre; Arsenault, Benoit J.; Boekholdt, S Matthijs; Colhoun, Helen; DeMicco, David A; et al, Various; Hovingh, G Kees; LaRosa, John C.; Mora, Samia; Pedersen, Terje R; Tonkin, Andrew; Welch, K; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreLevels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis, Circulation, vol.128, 14, 2013,pp 1504-1512
2008Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin TreatmentBarter, Philip; Boekholdt, S Matthijs; Cater, Nilo B; Deedwania, Prakash; DeMicco, David A; Gaffney, Michael; Grundy, Scott M; Holme, Ingar; Kastelein, John J.P.; LaRosa, John C.; Olsson, Anders G; Pedersen, Terje R; Szarek, Michael; van der Steeg, Wim A; Central Clinical School: Heart Research InstituteLipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment, Circulation, vol.117, 23, 2008,pp 3002-3009
2016Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Liu, Thomas; Pedersen, Terje R; Sabatine, Marc S.; Scott, Rob; Sever, Peter; Wang, Huei; Wasserman, Scott M; NH&MRC Clinical Trials CentreRationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, American Heart Journal, vol.173, N/A, 2016,pp 94-101
2014Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trialsKeech, Anthony (Tony); Simes, Robert John; Amarenco, Pierre; Arsenault, Benoit J.; Boekholdt, S Matthijs; Colquhoun, David; DeMicco, David A; et al, Various; Hovingh, G Kees; LaRosa, John C.; Mora, Samia; Pedersen, Terje R; Waters, David; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreVery low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, Journal of the American College of Cardiology, vol.64, 5, 2014,pp 485-494